We help customers meet the challenges of assessing product potential and allocating resources across their portfolios – this, at a time when fewer new products are being launched, managed care is having a significant impact and competition is escalating.

IMS data has always been at the core of Portfolio Optimization – from global overviews to regional and national surveys... from sales volume and market share to prescribing trends by product, company, geography and distribution channel.

Our prescription audits, the industry gold standard, tell customers what physicians are prescribing – and what pharmacists are dispensing – in markets throughout the world.  Medical audits, available in more than 45 countries, describe both the occurrence and treatment of diseases – enabling IMS to recommend the best R&D investments, based on projected future therapy choices by physicians. We draw on these and other information assets to design offerings that rise to the challenge of optimizing pharma product portfolios, providing actionable answers to their most critical portfolio issues:

• What products to license?
• Which therapy classes to enter?
• Which drugs get the marketing money and which do not?
• How will a client’s current portfolio perform over the next 3-5 years?

To get these answers, IMS creates tailored solutions combining the power of our data and applications with our team’s expertise.

Our Portfolio Optimization offerings support decision-makers in key areas that include:

• Market Opportunity Assessment
• Strategic Planning
• New Business Development
• Market Analysis

	To learn more about how IMS can help your company, contact us. For regional contact information, click here.

email this page     print this page